FLGT vs. PACS, PGNY, TDOC, FTRE, NHC, VRDN, AHCO, CDNA, AGL, and PNTG
Should you be buying Fulgent Genetics stock or one of its competitors? The main competitors of Fulgent Genetics include PACS Group (PACS), Progyny (PGNY), Teladoc Health (TDOC), Fortrea (FTRE), National HealthCare (NHC), Viridian Therapeutics (VRDN), AdaptHealth (AHCO), CareDx (CDNA), agilon health (AGL), and The Pennant Group (PNTG). These companies are all part of the "healthcare" industry.
Fulgent Genetics vs.
Fulgent Genetics (NASDAQ:FLGT) and PACS Group (NYSE:PACS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, community ranking, risk, institutional ownership, earnings, dividends and analyst recommendations.
In the previous week, PACS Group had 40 more articles in the media than Fulgent Genetics. MarketBeat recorded 42 mentions for PACS Group and 2 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 1.14 beat PACS Group's score of 0.04 indicating that Fulgent Genetics is being referred to more favorably in the media.
Fulgent Genetics presently has a consensus target price of $22.00, indicating a potential upside of 28.43%. PACS Group has a consensus target price of $34.00, indicating a potential upside of 148.72%. Given PACS Group's stronger consensus rating and higher possible upside, analysts clearly believe PACS Group is more favorable than Fulgent Genetics.
48.1% of Fulgent Genetics shares are owned by institutional investors. 31.8% of Fulgent Genetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
PACS Group has higher revenue and earnings than Fulgent Genetics.
Fulgent Genetics received 221 more outperform votes than PACS Group when rated by MarketBeat users. However, 95.83% of users gave PACS Group an outperform vote while only 60.10% of users gave Fulgent Genetics an outperform vote.
PACS Group has a net margin of 0.00% compared to Fulgent Genetics' net margin of -59.39%. PACS Group's return on equity of 0.00% beat Fulgent Genetics' return on equity.
Summary
PACS Group beats Fulgent Genetics on 10 of the 15 factors compared between the two stocks.
Get Fulgent Genetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FLGT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fulgent Genetics Competitors List
Related Companies and Tools
This page (NASDAQ:FLGT) was last updated on 1/15/2025 by MarketBeat.com Staff
